Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
GRK 4 CRISPR/Cas9 KO Plasmid (h): sc-402816
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GRK 4 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the GRK 4 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: GRK 4 Antibody (D-11): sc-376891
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GRK 4 CRISPR/Cas9 KO Plasmid (h) | sc-402816 | 20 µg | $397.00 |
Overview
GRK4 encodes G protein-coupled receptor kinase 4 (GRK 4), a serine/threonine kinase that phosphorylates activated GPCRs to promote β-arrestin recruitment, receptor desensitization, and trafficking. GRK4 activity influences signaling dynamics in pathways linked to cAMP/PKA and downstream MAPK outputs by shaping the intensity and duration of receptor-mediated responses. In kidney and vascular-relevant contexts, GRK4 has been studied for its effects on dopaminergic receptor regulation and sodium handling, connecting it to blood pressure regulation phenotypes. Altered GRK4 expression or functional variants have been associated with cardiovascular and renal research areas where GPCR signaling homeostasis is disrupted.
GRK 4 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the GRK4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the GRK4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the GRK4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish GRK 4 protein expression.
This CRISPR knockout system enables efficient generation of GRK4-deficient cell models for investigation of GRK 4 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting GRK4 exon(s) critical for GRK 4 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple GRK4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by GRK 4 CRISPR/Cas9 KO Plasmid (h) and GRK 4 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the GRK4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by GRK 4 HDR Plasmid (h) and GRK 4 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by GRK4 homology arms to support homology-directed repair at defined GRK4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.